ema retatrutide approval Who Makes Retatrutide? Company Behind the Weight Loss Drug Phase 3 results for retatrutide

"The GIP and GLP-1 Function Shows Promising Results." [3] McCarty, M

PubMed, Gupta, Dharmendra Kumar, and Arunima Chaudhuri

Efficacy In the original phase 3 randomized trials for obesity, average weight reduction compared to placebo has ranged from 5.3% to 17.8% after 56 to 72 weeks (Table 1), with improvements in several obesity-related risks and complications

[19] GLP-1 U.S

Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, Gonzalez JG, Chan M, et al

This study employed a multi-omics approach, integrating transcriptomic, metabolomic, and gut microbiota analyses, to identify key pathways and interactions underlying these metabolic disturbances (Song X